HORIZON (OP-106) Study of Melflufen in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety

Paul G. Richardson, MD; Albert Orlow, MD; Alessandra Larocca, MD; Paula Rodriguez Otero, MD; Maxim Horkin, MD; Joan Bladé, MD; Michele Cavo, MD; Hanu Hasson, MD; Xavier Lelu, MD, PhD; Adrià Alegren, MD; Christopher Maisel, MD; Agne Paner, MD; Amitabh Maumander, MD; Jeffrey A. Zender, MD, PhD;
Noemi Puig, MD; Jehan Hamenberg, MD; Sara Thorsness, MS; Hanan Zabair, MS; and Maria-Victoria Mateos, MD, PhD

Poster MM-250

Presented at the Annual Meeting of the Society for Hematologic Oncology (SOHO), September 11-14, 2019, Houston, Texas

BACKGROUND

SELECTIVE CYTOTOXICITY OF MELFLUFEN

Melflufen is a highly cytotoxic triazolo[1,5-a]pyrimidine, recently approved in the US for use in combination with daratumumab for RRMM after ≥3 prior lines of therapy. Melflufen cells in vitro due to increased intracellular alkylator acylation.

MELFLUFEN IN RRMM: 0–12 D & 119

Table 1. Baseline Patient Characteristics

Table 2. Prior Treatment and Refractory Status

Table 3. Treatment Received and Refractory Status

Table 4. Best Response for EMD and Melflufen Patients (n=121)

Table 5. Safety and Tolerability of Melflufen

Table 6. Dose Modifications Due to Toxids

RESULTS

CONCLUSIONS

REFERENCES

ACKNOWLEDGMENTS

DISCLOSURES

Oncopeptides